TS 172
Alternative Names: TS-172Latest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator Taisho Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 28 Oct 2024 Taisho Pharmaceutical completes a phase I mass balance trial (In volunteers) in Japan(PO) (NCT06596356)
- 26 Sep 2024 Taisho Pharmaceutical initiates enrollment in a phase I mass balance trial (In volunteers) in Japan(PO) (NCT06596356)
- 26 Sep 2024 Taisho Pharmaceutical plans a phase I trial (In volunteers) in an undisclosed location (PO) in September 2024 (NCT06596356)